Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Sporadic Thyroid Gland Medullary Carcinoma”

5 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 5 results

Not applicableStudy completedNCT06243965
What this trial is testing

Is Desmoplastic Stromal Reaction Useful to Modulate Lymph Node Dissection in Sporadic Medullary Thyroid Carcinoma?

Who this might be right for
Medullary Thyroid CancerMedullary CarcinomaMedullary Tumor+6 more
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 246
Large-scale testing (Phase 3)Study completedNCT00410761
What this trial is testing

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

Who this might be right for
Thyroid Cancer
Genzyme, a Sanofi Company 331
Testing effectiveness (Phase 2)Study completedNCT00390325
What this trial is testing

Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

Who this might be right for
Hereditary Thyroid Gland Medullary CarcinomaLocally Advanced Thyroid Gland Medullary CarcinomaMultiple Endocrine Neoplasia Type 2A+8 more
National Cancer Institute (NCI) 21
Testing effectiveness (Phase 2)Ended earlyNCT00923247
What this trial is testing

A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)

Who this might be right for
Medullary Thyroid Carcinoma
National Cancer Institute (NCI) 22
Not applicableStudy completedNCT01945762
What this trial is testing

Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer

Who this might be right for
Symptomatic, Aggressive, Sporadic, Unresectable, LocallyAdvanced/Metastatic Medullary Thyroid Cancer (MTC)
Genzyme, a Sanofi Company 31